In this medfyle

The decision to pursue allogeneic transplant in patients with NPM1-mutated AML during their first complete remission remains debated due to inconsistent worldwide data. A new study, utilizing prospective data from the UK, evaluated the impact of CR1-allo on overall survival based on peripheral blood NPM1 MRD status post-induction chemotherapy. Among patients in remission, those with positive MRD benefited significantly from CR1-allo. Conversely, MRD-negative patients showed no survival benefit from CR1-allo. These findings underscore the importance of MRD status in guiding transplant decisions for NPM1-mutated AML patients.